<DOC>
	<DOCNO>NCT00160511</DOCNO>
	<brief_summary>16 week trial assess efficacy , safety , tolerability levetiracetam compare placebo treatment postherpetic neuralgia .</brief_summary>
	<brief_title>A 16 Week Study Evaluating Levetiracetam Treatment Post Herpetic Neuralgia ( PHN )</brief_title>
	<detailed_description />
	<mesh_term>Neuralgia</mesh_term>
	<mesh_term>Neuralgia , Postherpetic</mesh_term>
	<mesh_term>Etiracetam</mesh_term>
	<mesh_term>Piracetam</mesh_term>
	<criteria>male female outpatient great equal 18 year age . suffer presently neuralgia , present least 3 month since heal acute herpes zoster skin rash . PHN pain entry study must meet following criterion : VAS least 40 mm visit 2 ( ass pain intensity past week ) average daily score least 4 PIS baseline period evaluate minimum 4 day . estimate creatinine clearance least 50 ml/min . receive professional psychological support ( cognitive behavioral therapy ) currently within 2 week prior visit 1 specifically cop PHN . previous neurolytic neurosurgical therapy PHN , time subject 's history treatment TENS ( transelectroneuro stimulation ) currently within past 2 week . know coexistent source pain painful peripheral neuropathy . know significant neurological disorder study disease condition mimic stroke distal neurological deficit ( amyotrophy , radiculopathy , history TIAs , multiple sclerosis , amputation ) . condition know associated immunosuppressive state . clinically significant major depression define Beck Depression Inventory Score &gt; 21 selection include history Bipolar Disorder .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2009</verification_date>
	<keyword>Postherpetic Neuralgia ( PHN )</keyword>
	<keyword>Levetiracetam</keyword>
	<keyword>Keppra</keyword>
	<keyword>Nerve Pain</keyword>
</DOC>